Ubiquitination plays a key role in regulating protein degradation, and is carried out by the conjugation of ubiquitin to target proteins through the sequential activity of three enzymes: E1, E2 and E3. Poly-ubiquitinated proteins are then subject to degradation by proteasomes.
The ubiquitin pathway is associated with many pathologies such as cancer, muscle atrophy, inflammation, viral infection, and metabolic and neurodegenerative disorders. The Ubiquitin-Eu cryptate allows flexible assay development assessing each step in the ubiquitin pathway.
The figure on the right summarizes the results of a p53 poly-ubiquitination assay*
Eu3+-labeled ubiquitin was directly incorporated into the poly-ubiquitin chain on the biotinylated-p53 target protein:
200 nM Biotinylated-p53 was incubated with 300nM E2, 150nM E3, 200nM ATP, and a mixture of Ub-K/Ub (20/500 nM).
8 nM E1 was then added to start the reaction,
The ubiquitin reaction was stopped at various times by adding EDTA.
Poly-ubiquitinated p53 was measured by the addition of streptavidin-XL665.
The enzymatic reaction was linear for up to 50 minutes. The assay had CVs <5% and a S/B of 10 that was stable for several days.
*The ubiquitin assay was performed following the procedure as described by Yabuki et al. in Comb Chem High Throughput Screening. 1999 Oct;2(5):279-87
Easy pharmacological characterization of PPI modulators. - Technical Notes
Deciphering low- and high affinity interactions - Application Notes
Monitoring nuclear receptor binding with HTRF assays - Application Notes
Challenge large complexes with HTRF assays - Application Notes